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Abstract
Background: At the time of the influenza A(H1N1)pmd09 pandemic it was not known if concurrent or sequential
administration of seasonal trivalent influenza vaccine (TIV) with pandemic vaccine was preferred.
Methods: Immunogenicity and safety were assessed in 871 healthy subjects aged 19–40 years who were
randomised into six groups to receive co-administration or sequential administration of TIV and two doses of
A(H1N1)pmd09 vaccine (either unadjuvanted or adjuvanted with AS03, an α-tocopherol and squalene-based
oil-in-water emulsion).
Results: Safety and immunogenicity data (by haemagglutination inhibition [HI] assay) after each dose and six
months post-Dose 1 are reported here. Co-administration of A(H1N1)pmd09 vaccine with TIV reduced the HI
immune responses to A(H1N1)pmd09 vaccine. However, serologic responses with both co-administration and
sequential schedules met the European and US regulatory criteria for pandemic and seasonal influenza vaccines up
to six months following the first vaccine dose. The AS03-adjuvanted formulation elicited higher immune responses
at all time points. Prior administration or co-administration of A(H1N1)pmd09 vaccine did not affect immune
responses to TIV.
Conclusions: Co-administration of TIV and A(H1N1)pmd09 vaccine negatively influenced A(H1N1)pmd09 vaccine
immunogenicity but had no effect on TIV responses. The non-adjuvanted and adjuvanted vaccines demonstrated
strong immune responses against all vaccine strains for up to six months following the first vaccine dose.
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Background
In contrast to seasonal influenza outbreaks, high attack
rates and substantive morbidity during the influenza
A(H1N1)pdm09 pandemic appeared in young persons
and adults under 65 years of age[1], and in subsequent
analyses more than 75% of A(H1N1)pmd09-related
deaths in the US were estimated to have occurred in
those aged 18–64 years[2]. Immunisation is considered
to be an essential component of public health strategies
to mitigate both seasonal and pandemic influenza illness
and mortality. As the first wave of the A(H1N1)pmd09
pandemic passed, and the second wave began in the
North American fall of that year, it was not known
whether seasonal trivalent inactivated influenza vaccine
(TIV) should be given before, after, or concurrently with
the pandemic vaccine, or at all, during a pandemic year.
Early results from a National Institute of Allergy and In-
fectious Diseases (NIAID) trial in 400 healthy adults
published online in October 2009 suggested that co-
administration of the two vaccines did not impair im-
mune response to either vaccine [3], but otherwise there
was little or no direct data on the immunogenicity and
safety of co-administration of TIV and pandemic influ-
enza vaccines to guide decision making.
In addition to the potential safety and immunogenicity
considerations of concurrent or sequential administra-
tion of TIV with a novel influenza vaccine antigen, it
was not known if pandemic vaccines using an oil-in-
water adjuvant would alter the immune response to TIV
given before, concurrently, or after the pandemic vac-
cine. The World Health Organization (WHO) recom-
mended production and use of oil-in water adjuvants
(and live attenuated influenza vaccines), based on an
anticipated limited vaccine availability on a global level
[4].
In this study the safety and immune responses to
A(H1N1)pmd09 pandemic vaccine, with or without AS03
adjuvant (an α-tocopherol and squalene-based oil-in-water
emulsion adjuvant system), following co-administration or
sequential administration of TIV, was evaluated in young
adults. Although serologic responses met regulatory cri-
teria for approval of such vaccines, co-administration was
associated with reduced A(H1N1)pmd09 vaccine im-
munogenicity. No effect on TIV immunogenicity was
observed, and both non-adjuvanted and adjuvanted vac-
cines demonstrated strong immune responses against all




Of the 871 subjects enrolled and screened, 611 sub-
jects were vaccinated; 580 and 561 subjects completed
Day 63 and Day 182 visits, respectively. Demographic
characteristics in the six study groups (TVC) were
similar. The mean age of subjects was 28.8 years
(range: 19–40 years). The male to female ratio was
45.2%:54.8% and the majority of subjects (79.2%) were
of European/Caucasian ancestry.
The ATP cohort for immunogenicity at Day 63
included 541 subjects. The reasons for removal of sub-
jects from the immunogenicity analyses are shown in
Figure 1.
Recruitment began October 13, 2009 and the last
study visit occurred May 25, 2010 (Day 0 to Day 182).
Baseline data is seen in Table 1.
Outcomes
Immunogenicity
Co-administration of TIV with 15 μg unadjuvanted
or AS03-adjuvanted A(H1N1)pmd09 vaccines: effect
on immune response to A(H1N1)pmd09 HA antigen
Co-administration of TIV with the non-adjuvanted
15 μg HA A(H1N1)pmd09 vaccine did not influence
the immune responses to A(H1N1)pmd09 HA antigen.
Non-inferiority was demonstrated between participants
receiving two 15 μg doses of non-adjuvanted A(H1N1)
pmd09 vaccine 21 days apart with the first dose co-
administered with TIV (Group C), and those receiving
two 15 μg doses of non-adjuvanted H1N1 2009 vac-
cine 21 days apart without TIV (Group E). The lower
bound of 97.5% CI for group GMT ratio at Day 42
was >0.5 (Table 2). Although non-inferiority was
demonstrated according to protocol-specified criteria,
the point estimate of GMT was 30% lower when TIV
was co-administered with non-adjuvanted pandemic
vaccine (Group C), compared to when A(H1N1)pmd09
vaccine was administered alone.
Non-inferiority was not established between sub-
jects receiving two doses of AS03-adjuvanted 3.75 μg
HA A(H1N1)pmd09 vaccine with the first dose co-
administered with TIV (Group D), and subjects receiving
two doses of AS03-adjuvanted 3.75 μg HA A(H1N1)pmd09
vaccine without TIV (Group F). The lower bound of 97.5%
CI for group GMT ratio at Day 42 was marginally <0.5
(Table 2). The A/California/7/2009 GMTs at Day 42 were
about 37% lower when TIV was co-administered with
AS03-adjuvanted A(H1N1)pmd09 vaccine (Group D).
Previous TIV vaccination followed by 15 μg unadju-
vanted or AS03-adjuvanted A(H1N1)pmd09 vaccines:
effect on immune response to A(H1N1)pmd09 HA
antigen Subjects who had TIV followed by two doses of
non-adjuvanted A(H1N1)pmd09 vaccine (Group A)
were not non-inferior compared to those who had two
doses of non-adjuvanted A(H1N1)pmd09 vaccine with
TIV at Day 42 (Group E), (Table 2). A(H1N1)pmd09 spe-
cific HI GMTs were lower when TIV was administered
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prior to 15 μg A(H1N1)pmd09 pandemic vaccine than
when H1N1 2009 vaccine was administered alone (33%
lower for Group A on Day 42 vs Group E on Day 21 and
34% lower for Group A on Day 63 vs Group E on Day 42
Table 3).
Subjects immunized first with TIV followed by two
doses of AS03-adjuvanted A(H1N1)pmd09 vaccine
(Group B), had non-inferior immune responses to the
pandemic strain compared to those subjects receiving
two doses of AS03-adjuvanted A(H1N1)pmd09 vaccine
without previous TIV receipt (Group F). However, A
(H1N1)pmd09 specific HI GMTs were lower when TIV
was administered prior to adjuvanted A(H1N1)pmd09
pandemic vaccine than when adjuvanted A(H1N1)
pmd09 vaccine was administered alone (40% lower for
Group B on Day 42 vs Group F on Day 21and 31% lower
for Group B on Day 63 vs Group F on Day 42 Table 3).
Subjects who had TIV followed by two doses of AS03-
adjuvanted 3.75 μg HA A(H1N1)pmd09 vaccine (Group
B) had superior A(H1N1)pmd09 specific HI GMTs com-
pared to those who had TIV followed by non-adjuvanted
pandemic vaccine (Group A). The lower bound of 95%
CI for group GMT ratio was >1.0 (Table 2).
Although not a planned comparison, it is noted that
A(H1N1)pmd09 specific HI GMTs were superior when
TIV was given with adjuvanted vaccine (Group C) com-
pared to unadjuvanted vaccine (Group D) (Table 3).
Co-administration of TIV with A(H1N1)pmd09 vac-
cines: effect on TIV strain immunogenicity The
immune responses to the three TIV strains did not change
when TIV was co-administered with the A(H1N1)pmd09
vaccine whether AS03-adjuvanted (Group D) or non-
adjuvanted (Group C) and non-inferiority was established
in all planned comparisons compared to subjects adminis-
tered a single dose of TIV (Groups A and B pooled)
(Table 2).
A(H1N1)pmd09 vaccine followed by TIV: effect on
immune response to TIV strains Previous vaccination
with A(H1N1)pmd09 vaccine did not influence the im-
mune responses to the TIV strains. Non-inferiority was
established between subjects who received two doses of
AS03-adjuvanted or non-adjuvanted A(H1N1)pmd09
vaccine followed by TIV (Groups E or F), and subjects
receiving a single dose of TIV (Groups A and B pooled)
(Table 2).
CHMP and CBER criteria All six groups met the
CHMP and CBER immunogenicity guidance criteria for
the A(H1N1)pmd09 HA antigen, 21 days after the first
dose of the AS03-adjuvanted or non-adjuvanted formu-
lations (Table 2 and additional file 1). Following the sec-
ond vaccine dose, HI titres increased further.
Figure 1 Study design. Total vaccinated cohort (TVC): all subjects with at least one documented vaccine dose with available immunogenicity
results. According-to-protocol (ATP) cohort for immunogenicity: all evaluable subjects (i.e., those meeting all eligibility criteria, with no elimination
criteria during the relevant analysis interval), who received two vaccine doses and for whom assay results were available at Day 42.
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For the TIV strains, the CHMP and CBER criteria were
met in all groups, 21 days after TIV administration (Day
42 or Day 63) except in Group F against A/Brisbane/59/
2007 (SCR: 36.3% at Day 63 using Day 42 as baseline, but
83.5% and surpassing criteria at Day 63 using Day 0 as
baseline) (Table 4).
Six months after the first vaccine dose (Day 182), the
immune responses to A(H1N1)pmd09 HA antigen in all
groups continued to meet CHMP and CBER criteria.
Safety and reactogenicity
Solicited local symptoms were more common in recipi-
ents of AS03-adjuvanted vaccine compared to those who
received the non-adjuvanted A(H1N1)pmd09 vaccine
(86.5−95.0% v. 64.7−73.5%, subjects reported at least one
local symptom respectively). Injection site pain was the
most frequently reported solicited local symptom across
all groups (Groups B, D, F: 89.0%, 94.9%, and 95.0%, re-
spectively); injection site pain in recipients of non-
adjuvanted A(H1N1)pmd09 vaccine ranged from 66 to
73.5%. Grade 3 injection site pain was reported by ≤6.1%
of subjects across the groups, except Group B (16.0%
reported Grade 3 pain) (Figure 2A).
The overall incidence of solicited general symptoms
was similar in AS03-adjuvanted or non-adjuvanted
A(H1N1)pmd09 vaccine groups (76.9−85.3% v. 77.2
−78.4%, respectively). Fatigue and headache were the
most frequently reported solicited general symptoms
across all groups (41.0−58.6% and 48.5−58.0%, subjects
reported at least one general symptom respectively);
Grade 3 fatigue and headache were reported in ≤8.0% of
subjects (Figure 2B).
Unsolicited adverse events were similar between groups
up to Day 84 (55.9−66.7%). Nausea (Group A: 4.9%),
Table 1 Summary of demographic characteristics (ATP cohort for immunogenicity)
Characteristics parameters or categories A B C D E F Total
















Age (years) Mean 29.6 - 28.8 - 28.0 - 29.3 - 29.6 - 28.5 - 29.0 -
SD 6.30 - 6.46 - 6.41 - 6.21 - 6.45 - 6.19 - 6.34 -
Median 29.5 - 28.0 - 27.0 - 29.0 - 29.0 - 27.0 - 28.0 -
Minimum 19 - 19 - 19 - 19 - 19 - 19 - 19 -
Maximum 40 - 40 - 40 - 40 - 40 - 40 - 40 -
Gender Female 47 51.1 49 57.0 50 54.3 43 48.3 57 62.6 55 60.4 301 55.6
Male 45 48.9 37 43.0 42 45.7 46 51.7 34 37.4 36 39.6 240 44.4
Ethnicity American hispanic or latino 11 12.0 9 10.5 7 7.6 5 5.6 4 4.4 11 12.1 47 8.7
Not american hispanic or latino 81 88.0 77 89.5 85 92.4 84 94.4 87 95.6 80 87.9 494 91.3
Geographic
Ancestry
African heritage/african american 14 15.2 11 12.8 14 15.2 13 14.6 11 12.1 15 16.5 78 14.4
American indian or alaskan native 1 1.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
Asian - central/south asian heritage 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.1 1 0.2
Asian - east asian heritage 0 0.0 1 1.2 1 1.1 1 1.1 0 0.0 1 1.1 4 0.7
Asian - japanese heritage 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Asian - south east asian heritage 0 0.0 1 1.2 0 0.0 0 0.0 0 0.0 2 2.2 3 0.6
Native hawaiian or other pacific
islander
0 0.0 0 0.0 3 3.3 0 0.0 0 0.0 0 0.0 3 0.6
White - arabic/north african heritage 1 1.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
White - caucasian/european heritage 74 80.4 72 83.7 73 79.3 75 84.3 78 85.7 70 76.9 442 81.7
Other 2 2.2 1 1.2 1 1.1 0 0.0 2 2.2 2 2.2 8 1.5
A = TIV+Pl d0, 15 mcg d21,42.
B = TIV+Pl d0, 3.75 mcg Adj d21,42.
C = 15 mcg + TIV d0, 15 mcg d21, Pl d42.
D = 3.75 mcg Adj + TIV d0, 3.75 mcg Adj d21, Pl d42.
E = 15 mcg + Pl d0, 15 mcg d21, TIV d42.
F = 3.75 mcg Adj + Pl d0, 3.75 mcg Adj d21, TIV d42.
N = total number of subjects.
n/% = number/percentage of subjects in a given category.
Value = value of the considered parameter.
SD = standard deviation.
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cough (Group C: 2.9%; Group E: 3.0%), oropharyngeal
pain (Group B: 6.7%; Group C: 2.9%; Group D: 7.0%;
Group F: 4.9%), rhinorrhoea (Group C: 2.9%), nasal con-
gestion (Group E: 3.0%) were the most frequently
recorded unsolicited adverse events considered to be caus-
ally related to vaccination; <5.0% of subjects reported un-
solicited adverse events of Grade 3 intensity that were
considered to be causally related to vaccination by local
investigators; 23.8−37.3% of subjects reported unsolicited
adverse events that prompted a medical visit.
Seven serious adverse events including one potential
immune-mediated-disease (pIMD) were recorded for six
subjects to the Day 182 follow-up time point. One of the
SAEs (subject with elevated alanine transaminase con-
sidered by the investigator to be of Grade 3 intensity
and required medical attention) was considered by the
investigator to be possibly vaccination-related. The sin-
gle pIMD (facial palsy of Grade 2 intensity) was consid-
ered by the investigator to be unrelated to the study
vaccines. All SAEs including the pIMD were resolved by
Table 2 Non-inferiority outcomes of Haemagglutination Inhibition (HI) antibody geometric mean titres (GMT) ratio
(ATP cohort for immunogenicity)
Ratio order Strain Adjusted GMTa ratio Non-inferiority criteria
TIVb co-administration Value [97.5% CIc]
Group D Day 42/Group F Day 42 A/California/7/2009 0.62 [0.48-0.81] If the lower bound of 95% CI for GMT ratio between
Group D Day 42; Group F Day 42 was >0.5
Group C Day 42/Group E Day 42 A/California/7/2009 0.66 [0.51-0.85] If the lower bound of 95% CI for GMT ratio between
Group C Day 42; Group E Day 42 was >0.5
Sequential administration Value [95% CI]
Group B Day 63/Group F Day 42 A/California/7/2009 0.68 [0.54-0.86] If the lower bound of 95% CI for GMT ratio between
Group B Day 63; Group F Day 42 was >0.5
(TIV prior to adjuvanted H1N1 vaccine)
Group A Day 63/Group E Day 42 A/California/7/2009 0.60 [0.48-0.76] If the lower bound of 95% CI for GMT ratio between
Group A Day 63; Group E Day 42 was >0.5
(TIV prior to unadjuvanted H1N1 vaccine)
Group B Day 63/Group A Day 63 A/California/7/2009 2.69 [2.14-3.39] If the lower bound of 95% CI for GMT ratio between
Group B Day 63; Group A Day 63 was >0.5;
Superiority criteria: Lower bound >1.0(adjuvanted H1N1/unadjuvanted H1N1)
Immune response to seasonal influenza strains Value [95% CI]
Group D Day 21/Group A+B Day 21 A/Brisbane/59/2007 0.91 [0.70-1.17] If the lower bound of 95% CI for GMT ratio between
Group D Day 21; Group A+B Day 21 was >0.5
(co-administration, adjuvanted) A/Uruguay/716/2007 1.15 [0.81-1.63]
B/Brisbane/60/2008 0.92 [0.74-1.15]
Group C Day 21/Group A+B Day 21 A/Brisbane/59/2007 1.23 [0.96-1.58] If the lower bound of 95% CI for GMT ratio between
Group C Day 21; Group A+B Day 21 was >0.5
(co-administration, unadjuvanted) A/Uruguay/716/2007 1.15 [0.81-1.63]
B/Brisbane/60/2008 0.74 [0.60-0.92]
Group F Day 63/Group A+B Day 21 A/Brisbane/59/2007 0.96 [0.75-1.24] If the lower bound of 95% CI for GMT ratio between
Group F Day 63; Group A+B Day 21 was >0.5
(Sequential adjuvanted) A/Uruguay/716/2007 1.20 [0.85-1.69]
B/Brisbane/60/2008 1.00 [0.81-1.24]
Group E Day 63/Group A+B Day 21 A/Brisbane/59/2007 0.84 [0.65-1.08] If the lower bound of 95% CI for GMT ratio between
Group E Day 63; Group A+B Day 21 was >0.5
(Sequential unadjuvanted) A/Uruguay/716/2007 1.24 [0.88-1.76]
B/Brisbane/60/2008 0.94 [0.76-1.17]
aGMT: Geometric Mean Titre.
bTIV: Trivalent inactivated influenza vaccine.
cCI: Confidence Interval.
BOLD : values of adjusted GMT ratio that did not met the pre-specified criteria.
Group definitions:
Group A: TIV+Placebo (Day 0); 15 μg (Day 21); 15 μg (Day 42).
Group B: TIV+Placebo (Day 0); 3.75 μg/AS03 (Day 21); 3.75 μg/AS03 (Day 42).
Group C: 15 μg+TIV (Day 0); 15 μg (Day 21); Placebo (Day 42).
Group D: 3.75 μg/AS03+TIV (Day 0); 3.75 μg/AS03 (Day 21); Placebo (Day 42).
Group E: 15 μg+Placebo (Day 0); 15 μg (Day 21); TIV (Day 42).
Group F: 3.75 μg/AS03+Placebo (Day 0); 3.75 μg/AS03 (Day 21); TIV (Day 42).
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Table 3 Haemagglutination inhibition antibodies against vaccine homologous A/California/7/2009 strain [CHMP/CBER
criteria] (According To Protocol cohort for immunogenicity)
Immune response Time
point





Day 0: 15 μg
+TIV
Day 0: 3.75 μg/
AS03+TIV
Day 0: 15 μg
+Placebo


























Value or % [95% CIb]
Day 21 Na=92 N=86 N=92 N=88 N=91 N=91
Day 42 N=92 N=86 N=92 N=88 N=91 N=91
Day 63 N=92 N=86 N=92 N=88 N=91 N=91
Day 182 N=92 N=89 N=85 N=88 N=89 N=91
Seroconversion rate Day 21 20.7% 23.3% 87.0% 95.5% 93.4% 97.8%
[CBERc: LLe of 95% CI >40%] [12.9-30.4%] [14.8-33.6%] [78.3-93.1%] [88.8-98.7%] [86.2-97.5%] [92.3-99.7%]
[CHMPd: point estimate >40%] Day 42 85.9% 96.5% 91.3% 96.6% 96.7% 98.9%
[77.0-92.3%] [90.1-99.3%] [83.6-96.2%] [90.4-99.3%] [90.7-99.3%] [94.0-100%]
Day 63 85.9% 97.7% 91.3% 95.5% 94.5% 98.9%
[77.0-92.3%] [91.9-99.7%] [83.6-96.2%] [88.8-98.7%] [87.6-98.2%] [94.0-100%]
Day 182 76.1% 87.6% 78.8% 89.8% 87.6% 92.3%
[66.1-84.4%] [79.0-93.7%] [68.6-86.9%] [81.5-95.2%] [79.0-93.7%] [84.8-96.9%]
Seroprotection rate Day 0 25.0% 10.5% 19.6% 18.2% 13.2% 13.2%
[CBER: LL of 95% CI >70%] [16.6-35.1%] [4.9-18.9%] [12.0-29.1%] [10.8-27.8%] [7.0-21.9%] [7.0-21.9%]
[CHMP: point estimate >70%] Day 21 48.9% 39.5% 96.7% 98.9% 97.8% 100%
[38.3-59.6%] [29.2-50.7%] [90.8-99.3%] [93.9-100%] [92.3 -99.7%] [96.0-100%]
Day 42 97.8% 100% 100% 100% 100% 100%
[92.4-99.7%] [95.8-100%] [96.1-100%] [95.9-100%] [96.0-100%] [96.0-100%]
Day 63 97.8% 100% 100% 100% 98.9% 100%
[92.4-99.7%] [95.8-100%] [96.1-100%] [95.9-100%] [94.0-100%] [96.0-100%]
Day 182 90.2% 97.8% 92.9% 100% 94.4% 97.8%
[82.2-95.4%] [92.1-99.7%] [85.3-97.4%] [95.9-100%] [87.4-98.2%] [92.3-99.7%]
Geometric mean fold rise Day 21 2.1 2.4 21.3 33.7 38.4 65.3
[1.8-2.6] [1.9-3.0] [16.4-27.7] [26.0-43.6] [29.3-50.5] [51.1-83.5][CHMP: point estimate >2.5]
Day 42 16.3 36.5 20.9 54.9 41.5 92.4
[12.6-21.1] [28.9-46.0] [16.3-26.7] [42.1-71.7] [32.4-53.2] [73.3-116.3]
Day 63 17.4 59.4 18.8 39.8 37.0 69.7
[13.4-22.6] [46.6-75.7] [14.7-24.1] [31.2-50.7] [28.6-47.9] [55.1-88.1]
Day 182 9.5 17.7 11.1 15.1 21.9 32.5
[7.3-12.4] [14.3-21.8] [8.6-14.4] [11.9-19.1] [16.4-29.4] [26.0-40.7]
Geometric mean titres Day 0 14.6 10.9 13.0 10.7 9.3 10.1
[11.2-19.0] [8.7-13.6] [10.2-16.5] [8.2-14.0] [7.7-11.4] [8.2-12.5]
Day 21 31.1 26.3 277.3 361.0 358.7 659.8
[24.0-40.3] [19.9-34.8] [222.4-345.7] [301.5-432.2] [285.0 -451.4] [546.0-797.4]
Day 42 238.6 396.2 271.2 589.8 387.1 933.1
[191.8-296.7] [329.2-476.8] [224.6-327.4] [517.8-671.8] [314.4-476.7] [815.6-1067.6]
Day 63 254.2 645.2 245.0 426.9 345.3 704.0
[210.1-307.7] [557.6-746.6] [200.7-299.1] [373.0-488.5] [278.6-428.0] [602.1-823.1]
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Day 182. There were no clinically relevant trends in la-
boratory test results and no evidence of differential hep-
atic or renal toxicities associated with receipt of the
adjuvant.
Discussion
The logistics of delivering a mass immunization program
are considerable, and concurrent administration of vac-
cines would be efficient for providers and more appeal-
ing to vaccinees than a requirement to make multiple
visits to a healthcare provider. During the influenza
A(H1N1)pmd09 pandemic, considerable variability in
administration of TIV and pandemic vaccines occurred,
with some authorities recommending co-administration,
and others recommending that TIV be given a month or
more after the pandemic vaccine. Of course, concurrent
administration of vaccines is desirable only when im-
munogenicity is not adversely effected, and safety is
similar or improved.
Although regulatory criteria for A(H1N1)pmd09 strain
immunogenicity were met in all vaccine groups at 21 days
after the first H1N1 dose and up to six months later, the HI
antibody response against the pandemic strain following
co-administration or sequential administration of TIV and
A(H1N1)pmd09 vaccines was decreased compared to when
A(H1N1)pmd09 vaccine was administered alone. Co-
administration of TIV with the first dose of pandemic
vaccine, or TIV administration 21 days prior to pandemic
vaccination, appeared to negatively influence the immune
response to the non-adjuvanted 15 μg HA A(H1N1)pmd09
vaccine and the AS03-adjuvanted 3.75 μg HA A(H1N1)
pmd09 vaccine to a similar degree (range of GMT dec-
rement 30.6% to 46.9%). This effect was similar at Day 63
and Day 182. This finding contrasts with data from studies
of concurrent TIV and monovalent A(H1N1)pmd09
vaccination which reported that sequential and simultan-
eous administration of A(H1N1)pmd09 influenza vaccine
and seasonal influenza vaccine did not influence the im-
mune responses to either vaccine antigens [3,5-7] . In con-
trast to our study, participants in these cited studies could
have received TIV in previous seasons compared to our
population of TIV-naive subjects. As well an older age
range of adults was included in other studies compared to
our population of 18 to 40 year olds, and different study
designs were used.
In a study in elderly adults (>64 years) using a similar
AS03-adjuvanted dose-sparing vaccine, evidence of mod-
est influence was also observed, though again with strong
immune responses against the vaccine homologous
A(H1N1)pmd09 strain when TIV was co-administered or
sequentially administered with A(H1N1)pmd09 vaccine
(GMTs: 227.5−309.8; SCRs: 64.2−97.6%) [5]. In a study of
adults including persons over 60 years, co-administration
of whole virion inactivated TIV and 6 μg HA inactivated
whole virion H1N1 2009 vaccine adjuvanted with alumin-
ium phosphate gel elicited strong immune responses
against both H1N1 strains and seasonal influenza strains
(GMFR: ~8.0 and 2.7−3.8; SCRs: ~81.0% and 40.3−70.7%,
respectively) [8].
Interestingly, TIV vaccination prior to pandemic vac-
cine in these TIV-naïve study participants increased,
moderately, A(H1N1)pmd09 specific HI titres in subjects
on Day 21 even before they received adjuvanted and
non-adjuvanted pandemic vaccines. Other studies also
suggest that prior TIV vaccination is associated with
increased pandemic specific antibody responses [9,10].
The mechanism of this phenomenon is not known, but
could be explained by lack of specificity of HI antibody
testing or cross-reactive antibody responses despite lack
of epitope similarity. Since up to 25% of subjects across
groups in the present study were seroprotected at base-
line, likely due to natural infection during the first wave
of the pandemic, many of these vaccine-naive partici-
pants could have had A(H1N1)pmd09 infection without
it being physician-diagnosed.
Immunogenicity to the TIV strains was unaffected
by co- or sequential administration with the AS03-
adjuvanted and non-adjuvanted H1N1 2009 vaccines;
the CHMP and CBER criteria were met in all groups,
21 days after TIV administration (Day 42 or Day 63) and
up to at least six months following the first TIV dose,
except in Group F against A/Brisbane/59/2007.
As has been previously demonstrated, use of an oil-in-
water adjuvant was associated with more robust immune
pandemic influenza A(H1N1)pmd09 responses at all
time points compared to use of non-adjuvanted 15 μg
Table 3 Haemagglutination inhibition antibodies against vaccine homologous A/California/7/2009 strain [CHMP/CBER
criteria] (According To Protocol cohort for immunogenicity) (Continued)
Day 182 136.6 206.9 151.7 171.7 218.5 323.6
[108.6-171.9] [171.3-249.9] [119.1-193.2] [143.2-205.8] [169.8-281.1] [268.8-389.5]
aN = Number of subjects with available results.
bCI = Confidence Interval.
cCBER = Center for Biologics Evaluation & Research.
dCHMP: Committee for Medicinal Products for Human Use.
eLL = Lower limit.
BOLD : values of SPR and Geometric mean fold rise that did not meet the pre-specified criteria.
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Value or % [95% CIa]
A/Brisbane/59/2007 Day 21 A 92 77.2% [67.2-85.3%] 93.5% [86.3-97.6%] 8.4 [6.5-10.8] 145.1 [115.9-181.6]
B 86 86.0% [76.9-92.6%] 97.7% [91.9-99.7%] 12.9 [10.0-16.6] 215.7 [168.2-276.5]
C 92 82.6% [73.3-89.7%] 96.7% [90.8-99.3%] 12.0 [9.4-15.4] 226.3 [181.4-282.2]
D 88 79.5% [69.6-87.4%] 92.1% [84.5-96.8%] 9.6 [7.7-12.1] 158.7 [127.9-197.1]
Day 42 E 91 18.7% [11.3-28.2%] 51.6% [40.9-62.3%] 2.3 [1.9-2.6] 32.9 [27.3-39.7]
F 91 30.8% [21.5-41.3] 68.1% [57.5-77.5%] 3.2 [2.7-3.8] 53.2 [43.5-65.1]
Day 63 A 92 68.5% [58.0-77.8%] 91.3% [83.6-96.2%] 6.9 [5.4-8.9] 120.2 [96.5-149.7]
B 86 88.4% [79.7-94.3%] 100% [95.8-100%] 11.2 [9.1-13.7] 186.5 [150.4-231.4]
C 92 75.0% [64.9-83.4%] 92.4% [84.9-96.9%] 8.4 [6.6-10.6] 157.0 [126.0-195.8]
D 88 72.7% [62.2-81.7%] 88.8%[80.3-94.5%] 7.6 [6.0-9.5] 124.3 [99.0-156.1]
E 91 78.0% [68.1-86.0%] 89.0% [80.7-94.6%] 9.4 [7.6-11.7] 137.4 [109.0-173.1]
F 91 83.5% [74.3-90.5%] 95.6% [89.1-98.8%] 10.1 [8.1-12.6] 166.9 [132.5-210.3]
Day 182 A 92 48.9% [38.3-59.6%] 68.5% [58.0-77.8%] 4.0 [3.1-5.3] 68.5 [53.6-87.4]
B 89 64.0% [53.2-73.9%] 83.1% [73.7-90.2%] 5.2 [4.2-6.6] 89.2 [71.0-112.0]
C 85 52.9% [41.8-63.9%] 77.6% [67.3-86.0%] 4.7 [3.7-6.0] 87.4 [68.5-111.5]
D 89 43.2% [32.7-54.2%] 68.5% [57.8-78.0%] 3.7 [2.9-4.8] 64.6 [51.4-81.1]
E 89 51.7% [40.8-62.4%] 75.3% [65.0-83.8%] 4.4 [3.5-5.4] 64.6 [51.4-81.1]
F 91 59.3% [48.5-69.5%] 78.0% [68.1-86.0%] 5.0 [4.0-6.3] 83.7 [66.0-106.2]
A/Uruguay/716/2007 Day 21 A 92 78.3% [68.4-86.2%] 84.8% [75.8-91.4%] 17.4 [13.0-23.3] 175.7 [129.6-238.2]
B 86 84.9% [75.5-91.7%] 89.5% [81.1-95.1%] 15.5 [11.8-20.4] 183.5 [135.2-248.9]
C 92 78.3% [68.4-86.2%] 83.7% [74.5-90.6%] 20.6 [14.8-28.6] 181.7 [128.1-257.9]
D 88 86.4% [77.4-92.8%] 88.8% [80.3-94.5%] 19.3 [14.2-26.4] 191.4 [138.4-264.7]
Day 42 E 91 3.3% [0.7-9.3%] 19.8% [12.2-29.4%] 1.2 [1.1-1.4] 12.5 [10.0-15.6]
F 91 6.6% [2.5-13.8%] 30.8% [21.5-41.3%] 1.7 [1.5-1.9] 19.1 [15.6-23.4]
Day 63 A 92 77.2% [67.2-85.3%] 84.8% [75.8-91.4%] 13.3 [10.0-17.6] 134.4 [100.4-179.9]
B 86 80.2% [70.2-88.0%] 87.2% [78.3-93.4%] 11.7 [9.1-15.0] 138.4 [104.8-182.7]
C 92 75.0% [64.9-83.4%] 79.3% [69.6-87.1%] 15.0 [11.2-19.9] 132.0 [94.9-183.7]
D 88 78.4% [68.4-86.5%] 84.3% [75.0-91.1%] 14.6 [10.9-19.6] 145.6 [107.7-196.8]
E 91 82.4% [73.0-89.6%] 89.0% [80.7-94.6%] 20.8 [15.5-28.0 216.1 [160.0-292.0]
F 91 85.7% [76.8-92.2%] 91.2% [83.4-96.1%] 19.3 [14.6-25.5] 221.9 [167.2-294.6]
Day 182 A 92 63.0% [52.3-72.9%] 71.7% [61.4-80.6%] 9.0 [6.7-11.9] 89.5 [65.8-121.8]
B 89 62.9% [52.0-72.9%] 71.9% [61.4-80.9%] 7.2 [5.6-9.3] 87.7 [64.0-120.3]
C 85 63.5% [52.4-73.7%] 70.6% [59.7-80.0%] 9.7 [7.2-13.1] 87.1 [61.4-123.5]
D 89 63.6% [52.7-73.6% 71.9% [61.4-80.9%] 8.5 [6.2-11.7] 87.8 [63.4-121.4]
E 89 67.4% [56.7-77.0%] 76.45 [66.2-84.85] 9.9 [7.3-13.5] 110.0 [79.3-152.6]
F 91 67.0% [56.4-76.5%] 76.9% [66.9-85.1%] 10.6 [7.9-14.2] 127.2 [92.3-175.5]
B/Brisbane/60/2008 Day 21 A 92 82.6% [73.3-89.7%] 98.9% [94.1-100%] 12.6 [9.8-16.2] 662.1 [545.4-803.8]
B 86 88.4% [79.7-94.3%] 98.8% [93.7-100%] 13.9 [11.1-17.5] 658.3 [540.2-802.0]
C 92 80.4% [70.9-88.0%] 97.8% [92.4-99.7%] 10.5 [8.3-13.5] 478.8 [389.5-588.6]
D 88 88.6% [80.1-94.4%] 100% [95.9-100%] 14.3 [11.0-18.7] 576.1 [479.8-691.8]
Day 42 E 91 6.6% [2.5-13.8%] 82.4% [73.0-89.65] 1.3 [1.1-1.5] 74.7 [61.4-90.9]
F 91 26.4% [17.7-36.7%] 97.8% [92.3-99.7%] 2.4 [2.0-2.8] 139.5 [120.0-162.2]
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HA A(H1N1)pmd09 vaccine (to be noted: 11 μg instead
of 15 μg HA was delivered). This observation has been
documented in all age groups tested and for influenza
antigen doses of 3.75 μg and 1.9 μg HA [11,12].
The high frequency of injection site pain with the
AS03-adjuvanted vaccine, is a consistent finding and in
agreement with other reports [10-12]. Grade 3 injection
site pain was uncommon. The incidence of general
symptoms between adjuvanted and unadjuvanted vac-
cine recipients were comparable.
Limitations
There are several limitations to our study. The sample
included TIV-naïve subjects, that is, adults less than
40 years of age without a history of receiving TIV or the
pandemic vaccine, in order to increase the likelihood
that subjects had little or no prior exposure to influenza
and reduce age-based immunogenicity-variation and
allowing for a smaller sample size. About 10.5 to 25% of
subjects were not naïve to the pandemic strain. Thus,
these results may not be generalizable to older adults or
those with prior influenza vaccine exposure. Also, the
pandemic virus was circulating during the trial, and may
have confounded vaccine immunogenicity. However this
is not likely to have affected one or more of the vaccine
groups disproportionately.
Conclusions
This study shows that the co-administration of the A
(H1N1)pmd09 vaccine with TIV did not alter the quanti-
tative immune response to TIV strains but influenced im-
mune response to A(H1N1)pmd09 strain. It is not known
if clinical protection would be affected by this reduced im-
mune response. Despite evidence of a lowered immune
response, both formulations met the CHMP and CBER
criteria for pandemic influenza vaccines, and continued to
do so up to six months after Dose 1 of vaccine. HI anti-
body GMTs were higher at all time points following vac-
cination with the AS03-adjuvanted 3.75 μg A(H1N1)




This was a randomised, observer-blind, controlled clin-
ical trial (Clinical trials registration NCT00985673) con-
ducted at four sites in the United States and three in
Canada (Table 5). Participants were randomised (alloca-
tion ratio 1:1:1:1:1:1) into six study groups (Groups A to
F; Figure 1).
Participants
Adults aged 19 to 40 years at the time of Dose 1 were
eligible if they were in stable health with a satisfactory
baseline medical assessment by history and physical
examination, safety laboratory results were within
protocol-specified limits and for women the pregnancy
test was negative and there was agreement to continue
adequate contraception for the study duration. Stable
health was defined as the absence of a health event satis-
fying the definition of a serious adverse event (SAE), or
a change in ongoing drug therapy due to therapeutic
failure or symptoms of drug toxicity within one month
prior to enrolment.
Exclusion criteria were a history of A(H1N1)pmd09
influenza vaccination or physician-confirmed infection,
prior receipt at any time of a seasonal influenza vaccine,
administration of any licensed vaccine within four
Table 4 Haemagglutination inhibition antibody immune responses against TIV strains (According To Protocol cohort
for immunogenicity) (Continued)
Day 63 A 92 79.3% [69.6-87.1%] 98.9% [94.1-100%] 9.6 [7.5-12.4] 506.7 [422.3-608.0]
B 86 84.9% [75.5-91.7%] 100% [95.8-100%] 10.0 [8.1-12.2] 471.2 [396.3-560.2]
C 92 72.8% [62.6-81.6%] 98.9% [94.1-100%] 7.9 [6.3-9.9] 359.6 [299.4-431.9]
D 88 83.0% [73.4-90.1%] 100% [95.9-100%] 10.8 [8.4-13.7] 433.5 [369.5-508.7]
E 91 85.7% [76.8-92.2%] 100% [96.0-100%] 11.4 [9.1-14.2] 644.9 [534.5-778.2]
F 91 83.5% [74.3-90.5%] 100% [96.0-100%] 11.9 [9.4-15.0] 688.1 [593.0-798.6]
Day 182 A 92 73.9% [63.7- 82.5%] 97.8% [92.4-99.7%] 6.7 [5.2-8.6] 339.9 [276.7-417.5]
B 89 60.7% [49.7-70.9%] 98.9% [93.9-100%] 5.7 [4.5-7.1] 273.8 [228.7-327.9]
C 85 56.5% [45.3-67.2%] 92.9% [85.3-97.4%] 5.5 [4.3-6.9] 245.4 [197.8-304.3]
D 89 72.7% [62.2-81.7%] 100% [95.9-100%] 6.8 [5.3-8.6] 292.6 [247.0-346.7]
E 89 75.3% [65.0-83.8%] 98.9% [93.9-100%] 6.9 [5.4-8.7] 369.6 [300.0-455.3]
F 91 68.1% [57.5-77.5%] 100% [96.0-100%] 6.4 [5.0-8.1] 378.4 [323.4-442.8]
aN = Number of subjects with available results.
bLL = Lower limit.
cCI = Confidence Interval.
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weeks, or any investigational product within 30 days pre-
ceding Dose 1, immunodeficient condition or receipt of
immunosuppressive drugs or of immunoglobulins/blood
products, diagnosis of cancer, allergy to vaccine constitu-
ents, pregnancy, acute febrile illness, unstable psychiatric
illness, disorder of coagulation or evolving neurologic
disorder.
Written informed consent was obtained from all sub-
jects prior to enrollment. The study was conducted in
accordance with Good Clinical Practice and the Declar-
ation of Helsinki. All study-related documents were
approved by the appropriate Institutional Review Boards:
the IWK Health Centre Research Ethics Board (Halifax,
Nova Scotia, Canada), IRB Services (Aurora, Ontario)
and Chesapeake Institutional Review Board (Austin,
Texas).
Interventions: study vaccines and immunization schedule
The A(H1N1)pmd09 pandemic influenza vaccine was a
monovalent, inactivated, split-virion antigen without or
with AS03 adjuvant system (ArepanrixTM, GlaxoSmithK-
line Vaccines). The H1N1 viral seed for the vaccine was
prepared from the reassortant virus NYMC X-179A
(New York Medical College, New York) generated from
Figure 2 Incidence and 95%CI of solicited local and general symptoms recorded during the 7-day post-vaccination follow-up period
(Total vaccinated cohort). Group definitions: Group A: TIV+Placebo (Day 0); 15 μg (Day 21); 15 μg (Day 42); Group B: TIV+Placebo (Day 0);
3.75 μg/AS03 (Day 21); 3.75 μg/AS03 (Day 42); Group C: 15 μg+TIV (Day 0); 15 μg (Day 21); Placebo (Day 42); Group D: 3.75 μg/AS03+TIV
(Day 0); 3.75 μg/AS03 (Day 21); Placebo (Day 42); Group E: 15 μg+Placebo (Day 0); 15 μg (Day 21); TIV (Day 42); Group F: 3.75 μg/AS03+Placebo
(Day 0); 3.75 μg/AS03 (Day 21); TIV (Day 42).
Table 5 Study sites
Country Province or State Number of sites Participants enrolled
Canada Quebec 2 225
Nova Scotia 1 61
USA Texas 2 195
North Carolina 1 37
Georgia 1 93
Total 7 611
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the A(H1N1)pmd09 strain, as recommended by the
World Health Organization (WHO) [4], and propagated
in embryonated hen eggs. AS03A is an Adjuvant System
containing α-tocopherol and squalene in an oil-in-water
emulsion (11.86 mg tocopherol). The AS03-adjuvanted
formulations were prepared on the day of vaccine ad-
ministration by an unblinded study nurse, by mixing the
antigen suspension and adjuvant emulsion (1:1).
The antigen suspensions were manufactured to con-
tain 15 μg/mL or 30 μg/mL haemagglutinin (HA) anti-
gen; AS03-adjuvanted vaccine was prepared from the
15 μg/mL suspension (3.75 μg HA/0.25 mL+0.25 ml
AS03: total vaccine dose=0.5 mL), while the non-
adjuvanted formulation was prepared from the 30 μg/
mL suspension (15 μg HA/0.5 mL). Approximately
11 months after release and following administration of
Dose 1 (Day 0), routine antigen stability testing using
the single radial immunodiffusion (SRID) assay indicated
that the 30 μg/mL lot had less than targeted HA con-
tent. As a result, 11 μg instead of 15 μg HA was admi-
nistered to subjects in Groups A, C and E. Antigen
potency was re-assessed by SRID after completion of
vaccination and remained stable at the same reduced
level of HA content. In this paper this formulation will
be referred by its intended dosage (15 μg). The HA anti-
gen content of the 15 μg/mL HA lot remained stable
and within the expected range.
The TIV was a split-virion vaccine (FluLavalTM, Glax-
oSmithKline Vaccines) formulated from the seasonal
strains A/Brisbane/59/2007, A/Uruguay/716/2007 and
B/Brisbane/60/2008. The antigen suspensions were man-
ufactured to contain 15 μg HA of each strain per 0.5 mL
doses.
Each 0.5 mL dose of A(H1N1)pmd09 vaccine and TIV
contained 5 μg and 50 μg of thimerosal as preservative,
respectively. All vaccines were administered intramuscu-
larly in the deltoid of the arm. The first study vaccines
were administered in each arm (Day 0), the second study
vaccine in the dominant arm (Day 21), and the final vac-
cine (Day 42) in the non-dominant arm.
The monovalent pandemic vaccine without adjuvant,
and the TIV were translucent to whitish suspensions.
The AS03 is a white liquid, and when mixed with influ-
enza antigen is a whitish emulsion.
Outcomes
Immunogenicity assessments
Serum samples were collected before vaccination, 21 days
after each vaccine dose and six months after the first
vaccine dose (Days 0, 21, 42, 63 and 182) and tested in
duplicate for haemagglutination inhibition (HI) titres
using a validated assay [cut-off: ≥1:10] with chicken ery-
throcytes as previously described [13] at GSK laboratory
(earlier timepoints tested together and D182 timepoint
tested later).
The magnitude of immune responses was evaluated
based on the immunogenicity criteria for pandemic influ-
enza vaccines in adults as required by the Committee for
Medicinal Products for Human Use (CHMP/EMA) [14];
point estimates for HI antibody seroconversion rate [SCR]:
>40%, seroprotection rate [SPR]: >70% and geometric
mean fold rise [GMFR]: >2.5) and the criteria for seasonal
influenza vaccines in adults as required by Center for Bio-
logics Evaluation and Research (CBER/USFDA; lower
bound of 95% confidence interval [CI] for HI antibody for
SCR: ≥40% and SPR: ≥70%) [15]. SCR was defined as the
percentage of subjects with pre-vaccination titre <1:10 and
post-vaccination titre ≥1:40, or pre-vaccination titre >1:10
and at least four-fold increase in post-vaccination titre,
SPR as percentage of subjects with a post-vaccination titre
≥1:40 and GMFR as post-vaccination fold increase in geo-
metric mean titres (GMTs).
Safety and reactogenicity assessments
Subjects used diary cards to record the occurrence and
intensity of solicited local and general symptoms and
unsolicited adverse events during the 7 and 21 day
follow-up period after each vaccine dose, and until Day
84. Intensity of solicited symptoms was graded on a
standard scale of [0–3]; Grade 1 symptoms defined as
those that were noticeable but did not interfere with
normal activities and Grade 3 symptoms defined as
those that prevented normal activities (Grade 3 redness
and swelling: diameter >100 mm; Grade 3 fever:
temperature ≥39 °C [≥102.2 °F]). Serious adverse events
and potential immune-mediated diseases (pIMDs: subset
of adverse events that include both autoimmune diseases
and other inflammatory and/or neurologic disorders
which may or may not have an autoimmune etiology)
occurring throughout the study period were also
recorded. Clinical laboratory parameters were assessed
at all seven visits up to Day 182.
Sample size
A sample size objectives of 600 subjects was estimated
to provide a power of 88.35% to evaluate each of the co-
primary objectives. The unevaluable subject rate was
estimated at ≤5%, the Log Standard Deviation for the
GMT assumed to be 0.6, and the type 1 error of 0.025.
The two co-primary objectives were evaluated in paral-
lel, in terms of GMT ratio adjusted by pre-vaccination
antibody titre. The study objective was considered met if
one of the co-primary objectives was met. Hence, 97.5%
confidence intervals (CIs) was used for the primary ob-
jective evaluation.
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Randomisation
Patients were randomized 1:1:1:1:1:1 to the six study
groups. The randomization was performed by the spon-
sor using MATEX, a program develop for use in SAS
(Cary, NC, USA) by GlaxoSmithKline (GSK) Vaccines,
Belgium which incorporated a minimization algorithm.
Study supplies were distributed to each study center by
blocks containing all vaccine supplies.
Patients were enrolled by trained study personnel.
Once eligibility was confirmed, specific unblinded study
personnel were responsible for determining vaccine allo-
cation as assigned by the internet based randomization
system at each vaccination visit, vaccine preparation,
and administration. The unblinded staff accessed the
randomization system on the internet and provided
the age and identification number of the participant.
The randomization system assigned a treatment number
which mapped to a vial number corresponding to sup-
plies at that study site. Vaccine reconstitution by the
unblinded nurse was done in a secure room, and then
the individual dose carried to the participant’s room on
a tray covered by an opaque cloth. The unblinded
personnel had no other role in the study.
Neither the subjects or blinded study personnel evalu-
ating the safety and immunogenicity endpoints were
aware of vaccine assignment until the data analysis was
completed.
Statistical methods
The primary objectives of this study were to evaluate
whether the immune response to A/California/07/2009
HA antigen in subjects who received a co-administration
of TIV with the first of two doses of either the non-
adjuvanted 15 μg HA vaccine or AS03-adjuvanted 3.75 μg
HA vaccine (Groups C or D) was non-inferior compared
to that in subjects who received two doses of these pan-
demic vaccines without TIV co-administration (Groups E
or F). The co-primary objectives were evaluated by the
group GMT ratio which was estimated via Analysis of co-
variance (ANCOVA) model on the logarithm transformed
titres, with post-vaccine dose as a response (dependent
variable) and baseline antibody level and vaccine group as
the independent variable (included all the vaccine groups).
The type-I error was adjusted for the parallel co-primary
objectives. The non-inferiority criteria would be met if the
lower bound of the 97.5% CI for GMR ratio at Day 42 be-
tween two groups (Groups D/F) OR (Groups C/E) was >
0.5.
The primary analyses of immunogenicity was per-
formed on the According-To-Protocol (ATP) cohort,
and of safety on the Total-Vaccinated-Cohort (TVC).
Secondary objectives included evaluation of the effect
of TIV vaccination 21 days prior to pandemic vaccin-
ation on the immune response to the A/California/07/
2009 HA antigen (Group A versus Group E and Group
B versus Group F as described above) and evaluation of
the effects of co-administration of pandemic vaccine and
TIV (Groups C or D) or sequential administration
(Groups E or F) on the immune response to each of the
three TIV HA antigens as compared to no previous pan-
demic vaccine administration (Groups A and B).
Solicited local, general symptoms and unsolicited ad-
verse events were summarized by vaccine group. No for-
mal statistical comparisons were performed between
groups for safety and reactogenicity (Table 6).
Additional file
Additional file 1: Figure S1. Haemagglutination inhibition antibodies
against vaccine homologous A/California/7/2009 strain [CHMP/CBER
criteria] (According To Protocol cohort for immunogenicity). Group
definitions: Group A: Group TIV+Plac/15/15: TIV+Placebo (Day 0); 15 μg
(Day 21); 15 μg (Day 42); Group B: Group TIV+Plac/AS/AS: TIV+Placebo
(Day 0); 3.75 μg/AS03 (Day 21); 3.75 μg/AS03 (Day 42); Group C: Group 15
+TIV/15/Plac: 15 μg+TIV (Day 0); 15 μg (Day 21); Placebo (Day 42); Group
D: Group AS+TIV/AS/Plac: 3.75 μg/AS03+TIV (Day 0); 3.75 μg/AS03 (Day
21); Placebo (Day 42); Group E: Group 15+Plac/15/TIV: 15 μg+Placebo
(Day 0); 15 μg (Day 21); TIV (Day 42); Group F: Group AS+Plac/AS/TIV:
3.75 μg/AS03+Placebo (Day 0); 3.75 μg/AS03 (Day 21); TIV (Day 42);
Dotted lines indicate the CHMP/CBER cut-off criteria for HI antibody
immune response against pandemic influenza strains in subjects aged
18–60 years (SCR: 40%; SPR: 70%; GMFR: 2.5).
Abbreviations
ATP: According To Protocol; CBER: Center for Biologics Evaluation & Research;
CHMP: Committee for Medicinal Products for Human Use; CI: Confidence
Interval; HA: Haemagglutinin; HI: Haemagglutination Inhibition; SD: Standard
Deviation; SRID: Single radial immunodiffusion; TIV: Trivalent Inactivated
Vaccine; TVC: Total Vaccinated Cohort; WHO: World Health Organization.
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